



Balloon-expandable TAVI valves have proven durability at 5 years with a promising outlook for the future




At 5 years, transcatheter valve implantation (TAVI) and surgical aortic valve replacement (sAVR) durability are equivalent¹



Mean aortic valve area: p=0.29; Mean valve gradient: p=0.92

There are no significant differences in¹:



All-cause mortality



Cardiovascular mortality




Stroke



Repeat hospital admission

Very few patients who received TAVI required reintervention due to structural valve deterioration (SVD)²


0.2%
Patients required
reintervention
due to SVD




2,482
Total patients

0.8%
Patients required
reintervention

TAVI valves are tested with even more rigorous criteria for measuring SVD and bioprosthetic valve failure (BVF)



Even so, studies still show very low rates of SVD and BVF at 8 years after TAVI⁴



At 2-year follow-up on the PARTNER 3 Trial, there was no change in mean gradient, aortic valve area or paravalvular regurgitation. Patients will be followed up to ten years.⁵



References: 1. Mack et al. Lancet 2015;385:2477-84. 2. Douglas et al. JAMA Cardiol 2017; 2(11): 1197-1206. 3. Dvir D, Bourguignon T, Otto CM, et al. Circulation. 2018;137(4):388-399. 4. Eltchaninoff H, et al. Eurointervention 2018; 14(3): e264-e271. 5. Mack MJ. Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial. Presented at: ACC 2020, Chicago, March 29, 2020.

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, and PARTNER 3 are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0141 v1.0

Edwards Lifesciences • 1919 Minnesota Court, Suite 501 Mississauga, ON L5N 0C9 • info.edwards.com/livingproof

